Breadcrumb

null Thierry Alcindor, MD

Investigator, RI-MUHC, Glen site

Cancer Research Program

Adjunct Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Medical Oncology, MUHC

 

Keywords

cancer • chemotherapy • clinical trials • sarcoma • colorectal cancer

Research Focus

My research focuses on designing and implementing experimental treatments for cancers of the digestive tract (esophagus, stomach, and colon) and of the musculoskeletal system (sarcomas), in order to improve results obtained with standard therapies.

Selected Publications

Click on Pubmed to see my current publications list

  • Demetri G, Chawla S, Ray-Coquard I, Le Cesne A, Staddon A, Milhem M, Penel N, Riedel R, Bui-Nguyen B, Cranmer L, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid J, Loewy J, Haluska F, Dodion P, Blay JY. Results of an international randomized phase 3 trial of the mTOR inhibitor, ridaforolimus, versus placebo to control metastatic sarcomas in patients following benefit from prior chemotherapy. Journal of Clinical Oncology. 2013 May 28. [Epub ahead of print]

  • Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, Niazi T, Garant A, Macheto D, Alcindor T, Vuong T. EGFR and K-ras gene mutation status in Squamous Cell Anal Carcinoma: A Role for Concurrent Radiation and EGFR Inhibitors? British Journal of Cancer. 2012 Nov 20; 107(11):1864-8. doi: 10.1038/bjc.2012.479. Epub 2012 Oct 23.

  • Alcindor T, Ferri LE, Marcus V, Andalib A, Hickeson M, Artho G, Chasen M, Thirlwell MP, Ades S. Perioperative DCF Chemotherapy Protocol for Patients with Gastroesophageal Adenocarcinoma: Correlation between Response to Treatment and Outcome. Medical Oncology. 2013 Mar; 30(1):377. doi: 10.1007/s12032-012-0377-7. Epub 2012 Dec 29.

  • Ferri LE, Ades S, Alcindor T, Chasen M, Hickeson M, Artho G, Marcus V, Thirlwell MP. Peri-Operative Docetaxel, Cisplatin, and 5-Flourouracil (DCF) for Locally Advanced Esophageal and Gastric Adenocarcinoma: Safety and Response Results from a Multi-Center Phase II Trial. Annals of Oncology. 2012 Jun; 23(6):1512-7. doi: 10.1093/annonc/mdr465. Epub 2011 Oct 29.

  • Mackay H, Au H, McWhirter E, Alcindor T, Jarvi A, MacAlpine K, Wang L, Wright JJ, Oza AM. A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium. Investigational New Drugs. 2012 Jun; 30(3):1158-63. doi: 10.1007/s10637-011-9650-4. Epub 2011 Mar 12.